Our objective was to study the ability of HuMax-IL15 , a human IgG1 anti-IL-15 monoclonal antibody , to neutralize exogenous and endogenous IL-15 activity in vitro and to perform a phase I-II dose-escalation trial with HuMax-IL15 in patients with active RA .
